Back4D Molecular Therapeutics Overview

4D Molecular Therapeutics Selling, General & Admin

Selling, General & Admin expenses for FDMT.

Quarterly SG&A Expenses

$11.69M
↓ 9.66% YoY

As of Mar 31, 2026

Annual SG&A Expenses (TTM)

$47.81M
↓ 5.91% YoY

Trailing 12 months ending Mar 31, 2026

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin